Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3468249 | 0.83 | CYP4F2 (0.44) | CYP4F2CYP4A11PKMMMP8METAP2 | |
| SCHEMBL8490035 | 0.81 | DGAT1 (0.32) | — | |
| SCHEMBL28724880 | 0.80 | CYP4F2 (0.38) | CYP4F2CYP4A11PKMMMP8METAP2 | |
| SCHEMBL1255383 | 0.80 | TSHR (0.32) | CYP3A4TSHR | |
| SCHEMBL23270827 | 0.79 | CYP4F2 (0.40) | CYP4F2CYP4A11PKMMMP8MAPT | |
| SCHEMBL14037348 | 0.78 | CYP4F2 (0.36) | CYP4F2CYP4A11MMP8MAPTALDH1A1 | |
| SCHEMBL12121809 | 0.77 | CYP4F2 (0.47) | CYP4F2CYP4A11PKMMMP8KDM4E | |
| SCHEMBL1253667 | 0.76 | CYP4F2 (0.46) | CYP4F2CYP4A11PKMMMP8KDM4E | |
| SCHEMBL9305198 | 0.76 | CYP4F2 (0.46) | CYP4F2CYP4A11PKMMMP8KDM4E | |
| SCHEMBL13623137 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043423-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2024-02-08 | — | — | US | disclosed |
| US-11718614-B2 | Compounds and methods for treatment of hedgehog pathway associated conditions | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-11718614-B2 | Compounds and methods for treatment of hedgehog pathway associated conditions | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-11718614-B2 | Compounds and methods for treatment of hedgehog pathway associated conditions | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2023-08-08 | — | — | US | disclosed |
| CN-113329996-B | Compounds and methods for treating hedgehog pathway related disorders | 博远医药(苏州)有限公司 | 2023-03-10 | — | — | CN | disclosed |
| US-20210214353-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2021-07-15 | — | — | US | disclosed |
| US-20210214353-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2021-07-15 | — | — | US | disclosed |
| EP-3810573-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | Suzhou Mednes Pharma Tech Co., Ltd. (CN) | 2021-04-28 | — | — | EP | disclosed |
| US-20200147064-A1 | Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor | AUTOIMMUNE PHARMA LLC (US) | 2020-05-14 | — | — | US | disclosed |
| WO-2018152405-A1 | REDUCTION OF PRO-INFLAMMATORY HDL USING A LEUKOTRIENE INHIBITOR | AUTOIMMUNE PHARMA LLC (US) | 2018-08-23 | — | — | WO | disclosed |
| WO-2007056220-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056220-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056228-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (GB) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-5420282-A | Inhibitors of leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1995-05-30 | — | — | US | disclosed |
| US-5399699-A | Lipoxygenase inihibitors, antiallergens, antiinflammatory agents | ABBOTT LABORATORIES (US) | 1995-03-21 | — | — | US | disclosed |
| WO-1994012179-A1 | INDOLE CARBOXYLATE DERIVATIVES WHICH INHIBIT LEUKOTRIENE BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1994-06-09 | — | — | WO | disclosed |
| US-5288743-A | Lipoxygenase inhibitors | ABBOTT LABORATORIES (US) | 1994-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105866-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | CYP4F2 544/4885CYP4A11 673/4885PKM 2875/4885 |
| US-11718614-B2 | Compounds and methods for treatment of hedgehog pathway associated conditions | SHH, GLI1, SMO | CYP4F2 1000/4885CYP4A11 553/4885PKM 2133/4885 |
| US-20240043423-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SHH, GLI1, SMO | CYP4F2 1048/4885CYP4A11 469/4885PKM 2183/4885 |
| US-20200147064-A1 | Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor | LTB4R, LTC4S, LTB4R2 | CYP4F2 1177/4885CYP4A11 384/4885PKM 3520/4885 |
| US-20210214353-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SHH, GLI1, SMO | CYP4F2 1000/4885CYP4A11 553/4885PKM 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.